Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplant
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hematologic Malignancies
Interventions
Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
UCARTCS1A
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 5 more
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Safety and Tolerability
Interventions
Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Drug
Lead sponsor
MerLion Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Conditions
Plasma Cell Myeloma
Interventions
Best Practice, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Gainesville, Florida • West Palm Beach, Florida + 20 more
Conditions
Refractory Multiple Myeloma
Interventions
Noscapine HCl
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Los Angeles, California • New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Samples USOPTIVAL Study

NCT04792684
Conditions
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Interventions
Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Diagnostic Test
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
16
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 11 more
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions
ACTR087, SEA-BCMA
Biological
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 4 more
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Busulfan, Melphalan, Bortezomib, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 72 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • The Bronx, New York
Conditions
Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions
Magellan®
Device
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Waldenstrom Macroglobulinemia
Interventions
Thalidomide, Lenalidomide, Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Hematologic Malignancy
Interventions
ANTI-CD45, CAMPATH-1H, FK506, Fludarabine, Total Body Irradiation, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Houston, Texas
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
Bendamustine hydrochloride, Bortezomib, Dexamethasone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Liver Cancer, Stage IV Renal Cell Cancer, Stage IV Rectal Cancer, Stage IV Lung Cancer, Stage IV Small Intestinal Cancer, Stage IV Gastric Cancer, Stage IV Bladder Cancer
Interventions
Canady Helios Cold Plasma Scalpel
Device
Lead sponsor
Jerome Canady, M.D.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Milwaukee, Wisconsin